Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA7 | P43166 | 1/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.36 |
| ▸ | CCR5 | P51681 | 1/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.35 |
| ▸ | FAAH | O00519 | 2/20 | 0.34 |
| ▸ | MAOA | P21397 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | RORC | P51449 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.32 |
| ▸ | AKT1 | P31749 | 2/20 | 0.32 |
| ▸ | PPIA | P62937 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5049959 | 0.72 | BCL2 (0.40) | GHSRCA12CA1CA7CA14 | |
| SCHEMBL5049958 | 0.72 | GHSR (0.35) | GHSRHSD11B1FAAH | |
| SCHEMBL13791907 | 0.71 | BCL2 (0.44) | GHSRCA12CA1CA7CA14 | |
| SCHEMBL25384603 | 0.70 | FAAH (0.62) | GHSRFAAH | |
| SCHEMBL4742076 | 0.70 | KMT2A (0.36) | GHSRCA12CA1CA7CA14 | |
| SCHEMBL17040898 | 0.69 | SSTR4 (0.47) | CA12CA1CA7CA14KMT2A | |
| SCHEMBL202837 | 0.68 | BTK (0.38) | GHSRFAAHKMT2AL3MBTL1 | |
| SCHEMBL7924261 | 0.68 | APOBEC3G (0.50) | CA12CA1CA7CA14HSD11B1 | |
| SCHEMBL19742568 | 0.68 | CTSL (0.52) | GHSRCA12CA1CA7CA14 | |
| SCHEMBL1143391 | 0.68 | CTSL (0.51) | CA12CA1CA7CA14KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080207528-A1 | Administering derivatives of 4-(3-pyrrolidinyloxy)quinoline | TAIGEN BIOTECHNOLOGY CO., LTD. (TW) | 2008-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207528-A1 | Administering derivatives of 4-(3-pyrrolidinyloxy)quinoline | GLS2, SLC10A1, UGT1A1 | GHSR 3301/4885CA12 2982/4885CA1 4273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.